Tony Piscopio, OnKure Therapeutics CEO
OnKure Therapeutics nabs $60M as HDAC inhibitor awaits solid-tumor readouts
OnKure Therapeutics has lined up $60 million in a new private funding round, adding to the Boulder, CO, biotech’s bank account as it works through …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
